Seoul St. Mary's Hospital

• Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

  Collaborator, Phase 4, Not yet recruiting, 2,300 people, 1 Oct 2026

• NCT06388720

  Collaborator, Phase 2, Recruiting, 82 people, 29 Apr 2024

• NCT06330038

  Collaborator, Phase 4, Recruiting, 5,384 people, 26 Mar 2024

• NCT06257394

  Collaborator, Phase 2, Recruiting, 74 people, 14 Feb 2024

• NCT06099366

  Collaborator, Phase 2, Recruiting, 116 people, 25 Oct 2023

• NCT04943653

  Phase 1/2, Status unknown, 61 people, 29 Jun 2021

• NCT04921189

  Collaborator, Phase 2, Completed, 160 people, 10 Jun 2021

• NCT04014803

  Collaborator, Phase 4, Recruiting, 3,500 people, 10 Jul 2019

• NCT03079427

  Collaborator, Phase 2, Completed, 101 people, 14 Mar 2017

• NCT02981212

  Collaborator, Phase 4, Status unknown, 100 people, 5 Dec 2016

• NCT02550665

  Collaborator, Phase 3, Completed, 176 people, 15 Sept 2015

• NCT02036554

  Phase 4, Status unknown, 234 people, 15 Jan 2014

• NCT01597934

  Collaborator, Phase 4, Status unknown, 104 people, 15 May 2012

• NCT01406704

  Phase 4, Terminated, 26 people, 1 Aug 2011

• NCT01277484

  Phase 1, Status unknown, 19 people, 17 Jan 2011

Sources: clinicaltrials.gov